+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia



Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia



European Journal Of Clinical Pharmacology. 45(2): 193



Terfenadine, a nonsedating H-1-selective antihistamine, is widely used in many countries. We report pharmacokinetic results in a patient who developed a prolonged QT-interval in ECG and symptomatic torsades de pointes ventricular tachycardia as a consequence of the interaction of itraconazole and terfenadine. Both drugs were taken in the recommended doses: terfenadine 60 mg b.d. and itraconazole 100 mg b.d. Terfenadine metabolism was delayed by itraconazole leading to an increased level of unmetabolised terfenadine. Seven weeks after the cessation of itraconazole treatment, terfenadine and rapidly metabolized to its active metabolite and did not prolong the QT-interval when given as a single provocation dose (120 mg). The findings suggest that intraconazole in therapeutic doses inhibits terfenadine metabolism. It is also possible that unmetabolised terfenadine alone, without an increased level of its active metabolite, may cause torsades de pointes. The concomitant use of terfenadine and itraconazole (and ketoconazole) should be avoided.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008930796

Download citation: RISBibTeXText

PMID: 8223844

DOI: 10.1007/bf00315505


Related references

Treatment with terfenadine and ketoconazole or itraconazole can cause torsades de pointes ventricular tachycardia. Duodecim; Laaketieteellinen Aikakauskirja 109(2): 164-166, 1993

Torsades de pointes ventricular tachycardia associated with terfenadine and paracetamol self medication. New Zealand Medical Journal 107(987): 402-403, 1994

Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?. British Journal of Pharmacology 166(4): 1490-1502, 2012

Torsades de pointes after terfenadine-itraconazole interaction. Bmj 306(6871): 186, 1993

Prevalence, therapeutic response, and outcome of ventricular tachycardia in the out-of-hospital setting: a comparison of monomorphic ventricular tachycardia, polymorphic ventricular tachycardia, and torsades de pointes. Academic Emergency Medicine 6(6): 609-617, 1999

Torsades de pointes ventricular tachycardia and terodiline. Lancet 338(8763): 344-345, 1991

Helicoidal ventricular tachycardia (Torsades de Pointes). Archivos del Instituto de Cardiologia de Mexico 47(1): 5-18, 1977

Sotalol and torsades de pointes ventricular tachycardia. Ugeskrift for Laeger 158(19): 2711-2716, 1996

Torsades de pointes-like polymorphic ventricular tachycardia in a dog. Journal of Veterinary Internal Medicine 8(6): 439-442, 1994

Flecainide induced ventricular tachycardia (torsades de pointes). Pacing and Clinical Electrophysiology 26(9): 1907-1908, 2003

The long QT/QT syndrome and the torsades de pointes ventricular tachycardia. Orvoskepzes 68(2): 99-111, 1993

Torsades de pointes ventricular tachycardia associated with overdose of astemizole. Mayo Clinic Proceedings 69(6): 589-593, 1994

Torsades de pointes versus polymorphous ventricular tachycardia. American Journal of Cardiology 52(5): 639-640, 1983

Torsades de pointes mimicking monomorphic ventricular tachycardia. Internal Medicine 49(22): 2521-2522, 2011

Polymorphic ventricular tachycardia and torsades de pointes: beyond etymology. Journal of Cardiovascular Electrophysiology 12(6): 695-696, 2001